Shire, a multinational maker of specialty biopharmaceuticals with operations in Chesterbrook, recently announced its acquisition of Lumena Pharmaceuticals Inc. of San Diego for $260 million or more, depending on conditions when the deal closes.
Lumena is said to offer liver disease treatment products that would complement Shire’s focus on rare diseases.
“These attractive potential treatments may offer new hope to patients with rare cholestatic liver disease and further contribute to Shire’s future growth,” Shire CEO Flemming Ornskov said in a press release.
“We are excited by the possibilities of these new assets in liver disease. We have the resources, the infrastructure and the operating capacity to invest in these new potential growth drivers, which add further value to Shire’s innovative pipeline.”
The United Kingdom-headquartered Shire itself may also be on the receiving end of an imminent buyout as drugmaker Allergan seeks to deflect “an unwanted takeover bid from Valeant Pharmaceuticals,” according to a Philly.com report.